Discriminating long myelitis of neuromyelitis optica from sarcoidosis

Annals of Neurology

Volumn 79, Issue 3, 2016, Pages 437-447

  Flanagan, Eoin P ^a   Kaufmann, Timothy J ^a   Krecke, Karl N ^a   Aksamit, Allen J ^a   Pittock, Sean J ^a   Keegan, B Mark ^a   Giannini, Caterina ^a   Weinshenker, Brian G ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AQUAPORIN 4; AZATHIOPRINE; BETA INTERFERON; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE; ECULIZUMAB; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; PREDNISONE; RITUXIMAB;

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOIMMUNITY; COMPARATIVE STUDY; CONTRAST ENHANCEMENT; CORTICOSTEROID THERAPY; DELAYED DIAGNOSIS; DEMYELINATION; FEMALE; HUMAN; IDIOPATHIC DISEASE; MAJOR CLINICAL STUDY; MALE; MYELITIS; MYELOOPTIC NEUROPATHY; NAUSEA AND VOMITING; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NEURITIS; PLEOCYTOSIS; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; SARCOIDOSIS; SPINAL CORD DISEASE; SPINAL CORD LESION; SPINAL CORD SARCOIDOSIS; SPINE RADIOGRAPHY; DIFFERENTIAL DIAGNOSIS; MIDDLE AGED; NEUROMYELITIS OPTICA; PROCEDURES; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; SPINAL CORD DISEASES; SYMPTOM ASSESSMENT; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEUROMYELITIS OPTICA; REPRODUCIBILITY OF RESULTS; SARCOIDOSIS; SENSITIVITY AND SPECIFICITY; SPINAL CORD DISEASES; SYMPTOM ASSESSMENT; YOUNG ADULT;

EID: 84960350160     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.24582     Document Type: Article

References (35)

1. Wingerchuk DM, Lennon VA, Lucchinetti CF, et al., The spectrum of neuromyelitis optica. Lancet Neurol 2007; 6: 805-815.
2. Wingerchuk DM, Banwell B, Bennett JL, et al., International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015; 85: 177-189.
3. Kitley JL, Leite MI, George JS, Palace JA,. The differential diagnosis of longitudinally extensive transverse myelitis. Mult Scler 2012; 18: 271-285.
4. Kim HJ, Paul F, Lana-Peixoto MA, et al., MRI characteristics of neuromyelitis optica spectrum disorder: an international update. Neurology 2015; 84: 1165-1173.
5. Flanagan EP, Weinshenker BG, Krecke KN, et al., Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders. JAMA Neurol 2015; 72: 81-87.
6. Stern BJ, Aksamit A, Clifford D, Scott TF,. Neurologic presentations of sarcoidosis. Neurol Clin 2010; 28: 185-198.
7. Flanagan EP, Weinshenker BG,. Neuromyelitis optica spectrum disorders. Curr Neurol Neurosci Rep 2014; 14: 483.
8. Lennon VA, Wingerchuk DM, Kryzer TJ, et al., A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004; 364: 2106-2112.
9. Fryer JP, Lennon VA, Pittock SJ, et al., AQP4 autoantibody assay performance in clinical laboratory service. Neurol Neuroimmunol Neuroinflammation 2014; 1: e11.
10. Pittock SJ, Lennon VA, Bakshi N, et al., Seroprevalence of aquaporin-4-IgG in a northern California population representative cohort of multiple sclerosis. JAMA Neurol 2014; 71: 1433-1436.
11. Sawaya R, Radwan W,. Sarcoidosis associated with neuromyelitis optica. J Clin Neurosci 2013; 20: 1156-1158.
12. Jiao Y, Fryer JP, Lennon VA, et al., Aquaporin 4 IgG serostatus and outcome in recurrent longitudinally extensive transverse myelitis. JAMA Neurol 2014; 71: 48-54.
13. Spencer TS, Campellone JV, Maldonado I, et al., Clinical and magnetic resonance imaging manifestations of neurosarcoidosis. Semin Arthritis Rheum 2005; 34: 649-661.
14. Stern BJ, Krumholz A, Johns C, et al., Sarcoidosis and its neurological manifestations. Arch Neurol 1985; 42: 909-917.
15. Sohn M, Culver DA, Judson MA, et al., Spinal cord neurosarcoidosis. Am J Med Sci 2014; 347: 195-198.
16. Bradley DA, Lower EE, Baughman RP,. Diagnosis and management of spinal cord sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2006; 23: 58-65.
17. Kim SH, Kim W, Huh SY, et al., Clinical efficacy of plasmapheresis in patients with neuromyelitis optica spectrum disorder and effects on circulating anti-aquaporin-4 antibody levels. J Clin Neurol 2013; 9: 36-42.
18. Weinshenker BG, O'Brien PC, Petterson TM, et al., A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 1999; 46: 878-886.
19. Bomprezzi R, Pati S, Chansakul C, Vollmer T,. A case of neurosarcoidosis successfully treated with rituximab. Neurology 2010; 75: 568-570.
20. Solomon AJ, Spain RI, Kruer MC, Bourdette D,. Inflammatory neurological disease in patients treated with tumor necrosis factor alpha inhibitors. Mult Scler 2011; 17: 1472-1487.
21. Judson MA, Baughman RP, Costabel U, et al., Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial. Eur Respir J 2008; 31: 1189-1196.
22. The Transverse Myelitis Consortium Working Group. Proposed diagnostic criteria and nosology of acute transverse myelitis. Neurology 2002; 59: 499-505.
23. Kim SM, Go MJ, Sung JJ, et al., Painful tonic spasm in neuromyelitis optica: incidence, diagnostic utility, and clinical characteristics. Arch Neurol 2012; 69: 1026-1031.
24. McGrath DS, Daniil Z, Foley P, et al., Epidemiology of familial sarcoidosis in the UK. Thorax 2000; 55: 751-754.
25. Lepur D, Peterkovic V, Kalabric-Lepur N,. Neuromyelitis optica with CSF examination mimicking bacterial meningomyelitis. Neurol Sci 2009; 30: 51-54.
26. Cohen-Aubart F, Galanaud D, Grabli D, et al., Spinal cord sarcoidosis: clinical and laboratory profile and outcome of 31 patients in a case-control study. Medicine (Baltimore) 2010; 89: 133-140.
27. Flanagan EP, O'Neill BP, Habermann TM, et al., Secondary intramedullary spinal cord non-Hodgkin's lymphoma. J Neurooncol 2012; 107: 575-580.
28. Junger SS, Stern BJ, Levine SR, et al., Intramedullary spinal sarcoidosis: clinical and magnetic resonance imaging characteristics. Neurology 1993; 43: 333-337.
29. Kumar N, Frohman EM,. Spinal neurosarcoidosis mimicking an idiopathic inflammatory demyelinating syndrome. Arch Neurol 2004; 61: 586-589.
30. Nesbit GM, Miller GM, Baker HL Jr, et al., Spinal cord sarcoidosis: a new finding at MR imaging with Gd-DTPA enhancement. Radiology 1989; 173: 839-843.
31. Kobayashi S, Nakata W, Sugimoto H,. Spinal magnetic resonance imaging manifestations at neurological onset in Japanese patients with spinal cord sarcoidosis. Intern Med 2013; 52: 2041-2050.
32. Yokote H, Nose Y, Ishibashi S, et al., Spinal cord ring enhancement in patients with neuromyelitis optica. Acta Neurol Scand 2015; 132: 37-41.
33. Flanagan EP, Hunt CH, Lowe V, et al., [(18)F]-Fluorodeoxyglucose-positron emission tomography in patients with active myelopathy. Mayo Clin Proc 2013; 88: 1204-1212.
34. Terushkin V, Stern BJ, Judson MA, et al., Neurosarcoidosis: presentations and management. Neurologist 2010; 16: 2-15.
35. Rosen Y,. Pathology of sarcoidosis. Semin Respir Crit Care Med 2007; 28: 36-52.